Home > Client Services > Client List > Astellas Pharma Ltd
 

Astellas Pharma Ltd Jobs Profile



This profile is a brief introduction for people seeking employment in pharmaceutical graduate jobs, pharmaceutical nurse advisors, pharmaceutical sales jobs, pharmaceutical training jobs, pharmaceutical sales management jobs, pharmaceutical marketing jobs, pharmaceutical executive jobs, or pharmaceutical clinical research associates who may be considering working for Astellas.

Company Overview

On 1 April 2005 Fujisawa and Yamanouchi officially merged to form Astellas Pharma Inc. The merger has created a company which ranks second in Japanese pharma market and around 17th overall in the global pharma market.

With ethical drugs as its core business, Astellas is a new force in the world pharmaceutical market. The Company has outstanding R&D and independent marketing ability which has a strong competitive edge in not only the domestic but also global markets. Astellas is committed to aggressively developing business and ensuring sustained increases in the corporate value as a "global pharmaceutical company originated in Japan" which contributes toward improving the health of people around the world through the provision of innovative and reliable pharmaceutical products.

Astellas is focused on three key therapy areas: urology, dermatology, and transplantation. These therapy areas are key to Astellas Europe and the organisation is committed to continuing to explore opportunities and to develop new products which will better serve patients affected by conditions across these areas.


Product Overview

Astellas Europe is primarily focused on three areas:

 - Urology- Vesicare, Flomax MR
- Dermatology- Protopic, Zineryt                       
- Transplantation

 

 



Claire
Astellas Pharma Ltd Account Manager
01494 818 025
(Mon to Fri 0830 to 1800 hours)
claireh@zenopa.com



Please contact the Account Manager for opportunities with this organisation

News

Astellas Phama and Maxygen announce global agreement
Astellas Pharma and Maxygen have signed a global agreement regarding the commercialisation rights to the MAXY-4 drug candidates for autoimmune diseases and transplant rejection.

Astellas announces plant transfer
Astellas Pharma has announced the sale and transfer of a plant owned by its Astellas Pharma Manufacturing subsidiary to APP Pharmaceuticals.

Astellas publishes annual report
Astellas Pharma has published its annual report covering the 2007 fiscal year.The company recorded a positive business performance during the period.

Astellas announces share purchase
Astellas Pharma has announced the acquisition of its treasury stock after it came to a decision on the specific method by which this move would be undertakenIt made this purchase pursuant to article 1...

Astellas 'believes in therapeutic value of Kynapid'
Astellas Pharma has reiterated its believe in the therapeutic value of Kynapid (vernakalant hydrochloride) injection as a treatment of atrial fibrillation.


home | our clients | browse news | browse jobs | links | hotel directory | copyright © 2008 Zenopa Ltd | terms & conditions of use